Giuseppe Nardo

Giuseppe Nardo, MD, is a Medical Oncology resident at the Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy. He graduated with honors in Medicine and Surgery from Università Cattolica del Sacro Cuore in Rome in 2022. His research focuses on translational cancer immunotherapy, with particular interest in adoptive cell therapies, and his current interest is to develop innovative immune-based approaches to overcome resistance mechanisms in solid tumors. In the year 2026-2027 his training period at the University of North Carolina, Chapel Hill (USA), under the supervision of dr Gianpietro Dotti will further enrich his technical lab skills and his preclinical research experience in order to pursue an MD-PhD after termination of residency in oncology, with the aim of becoming a physician scientist.

KET (2011), PET (2012), FCE (2015), IELTS (2025)

• PUBLISHED
• 1) Reviews
• - “Synergistic potential of antibiotics with cancer treatments”, Cancers (Basel), 2024
• - “Refining high-risk EGFR-mutant lung cancer patients: the role of adjusted variant allele frequency in first-line Osimertinib therapy”, Clinical Lung Cancer, 2025
• - “CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy”, The Journal for Immunotherapy of Cancer, 2026
• 2) Abstracts
• - “Survival Patterns in Large-Cell Neuroendocrine Carcinoma: Impact of Histology, Molecular Features, and Immunotherapy”, ESMO Sarcoma and rare cancers congress, 2026
• - “Enhancing CAR T Cell Therapy Through the Epigenetic Reprogramming of Memory Gene Transcriptional Circuits”, ESMO Open, 2026
• UNDER REVIEWING PROCESS
• - “Immune Cell Engagers and masking immunotherapy in solid tumors: focus on head and neck cancers”, Cancers (Basel)
• 2) Observational studies
• - “Transformation of Non-Small Cell Lung Cancer into Small Cell Lung Cancer: A Systematic Review with Exploratory Analysis”, Clinical Lung Cancer (ongoing approval)
• - “FL-REAL: First-Line REAL world study of the combinations nivolumab-ipilimumab and nivolumab-relatlimab in advanced melanoma”

Innovative Anticancer Therapy editions (2023, 2024, 2025, 2026), AIOM 2023 (Rome), ESMO 2025 (Berlin); AIOM-ESMO membership

(Presidential Decree no. 445 of 28/12/2000 and subsequent amendments) The undersigned Giuseppe Nardo, aware of the criminal liability provided for by art. 76 of Presidential Decree 445 (2000 and subsequent amendments) in the event of false statements or false acts, DECLARES That the information contained in this educational and professional curriculum vitae is true and correct.